One common ailment of adults nowadays is the rheumatoid arthritis. It is an autoimmune type of disease in which the immune system of the body attacks the joint. It means that the joints are being subjected to inflammation causing damage to both the cartilage and bones. Aside from the pain and discomfort that is commonly experienced by a person having a rheumatoid arthritis attack, it also causes disabling deformities, especially in the hand and feet. Fortunately, there are ways on how to prevent and stop the disease/attack from occurring.
Once recognized, it is vital for it to be treated before it can cause any more severe damage to the bones or the cartilage. The disease is like a tumor or cancer that progresses and thus if it is to be halted early on, it would help tremendously on the pain and discomfort in the later years.
Unfortunately for those who aren’t fans of taking pills, at present, the most common form of remedy for this disease is through medication. Taking disease-modifying antirheumatic drugs (DMARDs) is considered a reliable way of slowing or halting the progression of the disease. This drug has two types – the first one suppresses the body’s immune system, and the other one hones on certain inflammation producers. It had been categorized as biologics later on since they are synthesized from human genes.
Many researches have devoted their time in studies as to how the intervention by the DMARDs has impacted on the progression of the disease. One of the thing they did is to track down patients over a two year period. These patients took DMARDs and are classified as having ‘early rheumatoid arthritis’ since for the following year, the onset of the disease will strike. As per the study, out of the 833 patients that have been tracked down, more than 90% of them have showed symptoms showing that the disease’s progression has slowed down.
After six months of usage, 56% of the patients have achieved slow activity, which meant less swelling, inflammation and pain markers. After two years, these people who have used the drug at the earliest stage they could have a notably better experience with the disease compared to those who have only used the drug later on.
Researchers have also stated that the conventional use of DMARD doesn’t necessarily work just for everyone. There are some who might want to consider as using biologics combined with DMARD, while others opt to undergo surgical procedures for a longer lasting result. They have also noted that the ‘early window’ for one to intervene the disease’s progression is within three months since the disease has started. This is the period wherein the patient will start to develop joint inflammation.